Together, our data suggest the presence of important interplay between the endogenous metabolic dysregulation and development of an immunosuppressive TME through a Zeb1-dependent mechanism, highlighting the possibility of identifying new targets and therapeutic strategies for cancer treatment. Here, ZEB1 is linked to cancer.